In this insightful discussion, Kaspar Rufibach, an expert in statistical hypothesis testing, dives into the often-misunderstood world of p-values and confidence intervals. He explores the historical debates between Fisher’s and Neyman-Pearson’s approaches, shedding light on their practical implications. Kaspar shares real-world examples from clinical trials, emphasizing the risks of misinterpretation and the importance of clear communication. His tips for applying statistical concepts effectively can enhance collaboration with clinicians and strengthen the integrity of research.

Kaspar Rufibach, an influential statistician specializing in survival analysis, dives into the complexities of non-proportional hazards. He discusses the vital differences between hazard functions and survival functions while emphasizing their clinical relevance. The conversation highlights effective communication strategies for non-statisticians and the importance of innovative data visualization. Kaspar also explores challenges in trial design and suggests alternatives to traditional effect quantification methods, all aimed at enhancing the understanding of treatment dynamics in clinical settings.

Kaspar Rufibach, an expert in statistics, discusses managing hype in statistics. Topics include innovation waves, pressure on statisticians, rigor and honesty, building trust, proactive approach, and implementation challenges. The podcast emphasizes focusing on proven methods, establishing credibility, and staying ahead of trends.

Learn about the upcoming Effective Statistician Conference featuring speakers like Andy Grieve, Kaspar Rufibach, and Chrissie Fletcher. They discuss changes to the conference, the benefits of attending, and technical topics like biomarkers and structured equation modeling. The podcast also mentions upcoming presenters and conference sponsors.

Mouna Akacha and Kaspar Rufibach discuss promoting innovation in statistics, focusing on being collaborative, taking risks, and solving real-world problems. They highlight the need to improve communication, leadership, and adaptability skills. Investment in education, collaboration, networking, and advocacy is crucial for future innovation in drug development statistics.